Can MOTS‑c be used to treat menopausal symptoms?

MOTS-c is NOT recommended for treating menopausal symptoms

MOTS-c is an experimental mitochondrial-derived peptide that has no established role in menopause management and should not be used in clinical practice. There are no FDA-approved formulations, no clinical guidelines supporting its use, and insufficient human data to justify its application for menopausal symptoms 1.

Why MOTS-c Should Not Be Used

The only available evidence for MOTS-c in menopause is a single 2019 preclinical mouse study showing it prevented ovariectomy-induced obesity and insulin resistance through AMPK pathway activation 2. This is:

• Animal data only - no human trials exist
• Not FDA-approved for any indication
• Not mentioned in any clinical guidelines for menopause management
• Addresses metabolic dysfunction, not the primary menopausal symptoms (vasomotor symptoms, genitourinary syndrome)

What Should Be Used Instead

For Vasomotor Symptoms (Hot Flashes/Night Sweats)

First-line for women <60 years or <10 years post-menopause without contraindications:

• Menopausal hormone therapy (MHT) is the most effective treatment 1
  • Estrogen alone (ET) if no uterus
  • Estrogen plus progestogen (EPT) if uterus present
  • Use only FDA-approved preparations, not compounded hormones 1

For women with contraindications or who decline MHT:

• SSRIs/SNRIs, gabapentin, or pregabalin as first-line nonhormonal options 1
• Clonidine as second-line if first-line agents fail 1
• Fezolinetant (neurokinin receptor antagonist) shows promise but requires hepatotoxicity monitoring 3

For Genitourinary Syndrome of Menopause

First-line:

• Low-dose vaginal estrogen (cream, tablet, or ring) for vulvovaginal dryness, dyspareunia, and irritation 4
• Vaginal DHEA for dryness and dyspareunia 4
• Ospemifene (oral SERM) with caution due to endometrial stimulation and thrombosis risk 4

Risk Stratification Required

Avoid MHT in women with:

• Unexplained vaginal bleeding
• History of stroke, MI, PE, or VTE
• Breast or endometrial cancer
• Active liver disease 1

Exercise caution with:

• High cardiovascular disease risk - use nonhormonal therapies instead 1
• Moderate CVD risk - prefer transdermal estradiol with micronized progesterone 1

Critical Pitfalls

1. Do not use experimental peptides like MOTS-c - stick to evidence-based, FDA-approved therapies
2. Do not use compounded "bioidentical" hormones - guidelines explicitly recommend against this 1
3. Reassess MHT annually - target shortest duration consistent with treatment goals 1
4. Screen for breast cancer and cardiovascular risk before initiating any hormonal therapy 1

The evidence overwhelmingly supports established hormonal and nonhormonal therapies with proven efficacy and safety profiles. MOTS-c remains a research compound with no place in current clinical menopause management.